Nutriband Inc. has selected a worldwide brand name for its lead product, an abuse‑deterrent fentanyl transdermal system that uses the company’s AVERSA™ technology. The name was developed in partnership with Brand Institute, Inc. and will be submitted to the U.S. Food and Drug Administration and international trademark offices as part of the company’s 505(b)(2) NDA strategy.
The product targets the U.S. fentanyl patch market, which is estimated to be worth $1‑$2 billion annually. Nutriband’s first abuse‑deterrent patch could capture a share of that market and generate peak annual U.S. sales of $80 million to $200 million. The launch would position the company against established generic providers such as Johnson & Johnson, Teva, and Viatris, and would introduce a new safety feature that incorporates aversive agents to reduce abuse and accidental exposure.
Nutriband’s financial performance remains modest. For the fiscal year 2025, the company reported revenue of $2.14 million and a net loss of $10.48 million. In the quarter ending December 10 2025, revenue was $0.35 million, and the company posted a net loss that translated to an earnings‑per‑share loss of $0.32. The brand‑name announcement is a key commercial milestone that could improve the company’s long‑term revenue prospects, but the company continues to operate at a loss.
Chief Operating Officer Alan Smith said, “We are thankful for the opportunity to discuss the CMC aspects of our abuse‑deterrent fentanyl patch with the Agency. We are excited to incorporate the advice and constructive feedback that we received from the FDA into our development program as we move towards an IND filing in support of a Human Abuse Potential clinical study.” The company plans to submit the brand name to the FDA shortly and to advance the product through the remaining regulatory milestones.
The content on EveryTicker is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.